Ibuprofen really is a perfect example of this. As mentioned above, this petrochemical-derivative has been linked to significantly increased risk of heart attack and
increased cardiac and
all-cause mortality (when combined with aspirin), with over two dozen serious adverse health effects, including:
- Anemia.
- Anemia[1]
- Hearing Loss.
- DNA Damage[2]
- Influenza Mortality.
- Hearing Loss[3]
Ibuprofen is, in fact, not unique in elevating cardiovascular disease risk and/or mortality. The entire category of non-steroidal anti-inflammatory drugs (NSAIDs) appears to have this under-recognized dark side; cardiovascular disease and cardiac mortality score highest on the list of over 100 unintended adverse health effects associated with their use. See also our analysis of the rarely acknowledged dark side to aspirin: The Evidence Against Aspirin And For Natural Alternatives.
There is another take on Aspirin (Acetylsalicylic Acid and Salicylic Acid) from studies examined by Georgi Dinkov.
It seems that NSAIDs created by the pharmaceutical industry only take one portion of Salicylic Acid, and make a change so they can patent it. Salicyclic Acid has many more benefits than just pain relief, but you do have to be aware that ASA(aspirin) often come with coatings, or in a time release format, which negates a lot of the benefits of ASA. Try to find Aspirin that is not coated, i.e. 'quick release' or source Salicyclic Acid itself.
for example
haidut November 2, 2022 Posted in
Science
Share:
TwitterFacebookLinkedin
The link between NSAID usage (except aspirin) and heart attacks is not new, but I decided to still post this study due to the fact that it is the first to suggest those non-aspirin NSAID may actually damage the heart themselves rather than cause CVD events indirectly. Notably, once again, aspirin is missing from this list and this uniqueness of aspirin’s benefits was recently also seen in a COVID-19 study as well, where only aspirin did not increase mortality risk in COVID-19 patients. So, whatever aspirin does, it is beneficial for many conditions while the synthetic, selective COX inhibitors prescribed by doctors like candy have once again been proven to be dangerous.
Nonsteroidal Anti-Inflammatory Drugs May Trigger Heart Damage
“…The current study
10, presented at the European Society of Cardiology in Barcelona, Spain, demonstrated that
short-term use of NSAIDs is associated with heart failure in individuals with Type 2 diabetes.
11 The scientists wrote
12 that
a previous association had been made between NSAIDs and an increased risk of heart failure in the general population.
13 14 They sought to determine if using NSAIDs with Type 2 diabetes could increase the risk of heart failure, given that people with Type 2 diabetes have twice the risk of heart failure without using NSAIDs.
15 The researchers included 331,189 participants whose average age was 62 years.
Those who used NSAIDs claimed to have prescriptions of ibuprofen, diclofenac, naproxen, and celecoxib.”
haidut September 7, 2023 Posted in
Science
Share:
TwitterFacebookLinkedin
A fascinating study, which highlights once again that there is a lot more to aspirin than “COX inhibition” (as medicine would have us believe). The study was done on ICU patients only, but I view that as an even stronger evidence in favor of aspirin, since ICU patients are in a very precarious position and even benign things such as a little extra water or the wrong type of food (if they are even able to eat by themselves) can easily kill them. Thus, a substance that has such a strong effect on decreasing all-cause mortality in ICU patients should work even better on people who are not in the ICU. Another strong point of the study was that it included ICU patients with a plethora of conditions, not just heart disease (CVD). Unfortunately, the patients were all given just a baby aspirin dose since this is the only “preventive” dose the medical protocol in ICU (or hospitals in general) allows for, so we cannot make a direct claim that higher doses would have worked even better. However, other humans studies with severe chronic conditions (e.g. multiple sclerosis) have demonstrated that 2-4 tablets of aspirin lower mortality in those patients too, and there is also a yeast study showing that the human-equivalent dose (HED) of about 1g aspirin daily increased maximum lifespan by 400%! So, there does seem to be a dose-dependent benefit for aspirin dosage and for most people the benefits for overall health and lifespan probably continue to increase up to 2-3 tablets (325mg each) daily. For those who are prone to bleeding or concerned about aspirin’s pro-bleeding effects, taking 1mg vitamin K2 (MK-4) or 100mcg MK-7 for every tablet of aspirin taken daily should negate most of those bleeding risks (which are overblown by Big Pharma to start with).
Aspirin Therapy and 28-Day Mortality in ICU Patients: A Retrospective Observational Study From Two Large Databases - PubMed
“…Study limitation include it being a retrospective analysis where not all participant characteristics are recorded. There is also no record of the rationale for administering aspirin to participants. The investigators recommend future randomized controlled trials to further study the effects of aspirin in
ICU patients. “…
aspirin treatment in ICU patients, particularly those with SIRS symptoms and those without sepsis, led to lower 28-day all-cause mortality,” the study authors wrote.”
from PubMed link:
Observational Study
Clin Ther
. 2023 Apr;45(4):316-332.
doi: 10.1016/j.clinthera.2023.02.005. Epub 2023 Mar 25.
Aspirin Therapy and 28-Day Mortality in ICU Patients: A Retrospective Observational Study From Two Large Databases
Luhao Wang 1 ,
Bin Li 2 ,
Lingyun Zuo 3 ,
Fei Pei 3 ,
Yao Nie 3 ,
Yongjun Liu 3 ,
Zimeng Liu 3 ,
Jianfeng Wu 4 ,
Xiangdong Guan 3
Affiliations
Abstract
Purpose: Aspirin is widely used in patients in the intensive care unit (ICU); nonetheless, its effects on these patients remain controversial. This retrospective analysis of data from clinical practice investigated the effects of aspirin on 28-day mortality in ICU patients.
Methods: This retrospective study included data from patients in the Medical Information Mart for Intensive Care (MIMIC)-III database and the eICU-Collaborative Research Database (CRD). Patients aged 18 to 90 years and admitted to the ICU were eligible and were assigned to one of two groups according to whether they were given aspirin during their ICU stay. Multiple imputation was used for patients with >10% missing data. Multivariate Cox models and propensity score analysis were used to estimate the association of aspirin treatment with 28-day mortality among patients admitted to the ICU.
Findings: In total, 146,191 patients were enrolled in this study, and 27,424 (18.8%) used aspirin. Aspirin treatment in ICU patients, especially in nonseptic patients, was associated with a lower 28-day all-cause mortality on multivariate Cox analysis (eICU-CRD, hazard ratio
= 0.81, [95% CI, 0.75-0.87]; MIMIC-III, HR = 0.72 [95% CI, 0.68-0.76]). Aspirin treatment was associated with lower 28-day all-cause mortality after propensity score matching (eICU-CRD, HR = 0.80 [95% CI, 0.72-0.88]; MIMIC-III, HR = 0.80 [95% CI, 0.76-0.85]). However, on subgroup analysis, aspirin therapy was not associated with a lower 28-day mortality in patients without systemic inflammatory response syndrome (SIRS) symptoms or with sepsis in either database.
Implications: Aspirin treatment during the ICU stay was associated with a significantly reduced 28-day all-cause mortality, particularly in patients with SIRS symptoms but without sepsis. In patients with sepsis and with/without SIRS symptoms, beneficial effects were not clear, or more careful patient selection is required.
Keywords: anti-inflammation; aspirin; big data; critical care.
